Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION

Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 13, 2026
Income
$70,000.00
Expenses
Not reported
Filing UUID
1d6e7df2-1f82-4e8d-be17-f24583bd9521
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and on the tax base of the U.S. and its Territories. Issues related to the taxation of intellectual property income. Issues related to IRC sections 11, 41 and 174, 55, 56A, and 59, 59A, 163(j), 168(k), 250, 951A (H.R. 1990, S. 1639, H.R. 1347, S. 559, S. 1688, H.R. 574, S. 187, H.R. 1062, S. 1605, S. 2021, H.R. 1 - Sections 70301, 70302, 70303, 70321, 70322, 70323, 70331, 70341, 70342, 70361.)

Literal federal measure citations: H.R. 1990, S. 1639, H.R. 1347, S. 559, S. 1688, H.R. 574, S. 187, H.R. 1062, S. 1605, S. 2021, H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.